Literature DB >> 1629743

MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.

A Zuddas1, G Oberto, F Vaglini, F Fascetti, F Fornai, G U Corsini.   

Abstract

In cynomologus monkeys, systemic administration of MK-801, a noncompetitive antagonist for the N-methyl-D-aspartate receptor, prevented the development of the parkinsonian syndrome induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MK-801 also attenuated dopamine depletion in the caudate and putamen and protected dopaminergic neurons in the substantia nigra from the degeneration induced by the neurotoxin. Nevertheless, 7 days after MPTP administration in the caudate and putamen of monkeys also receiving MK-801, the levels of toxic 1-methyl-4-phenylpyridinium were even higher than those measured in monkeys receiving MPTP alone. This indicates that the protective action of MK-801 is not related to MPTP metabolism and strongly suggests that, in primates, the excitatory amino acids could play a crucial role in the mechanism of the selective neuronal death induced by MPTP.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1629743     DOI: 10.1111/j.1471-4159.1992.tb09429.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

1.  Neuroprotective potential of ionotropic glutamate receptor antagonists.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

Review 2.  The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases.

Authors:  J B Schulz; R T Matthews; T Klockgether; J Dichgans; M F Beal
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

Review 3.  Neurological dysfunction in methylmalonic acidaemia is probably related to the inhibitory effect of methylmalonate on brain energy production.

Authors:  M Wajner; J C Coelho
Journal:  J Inherit Metab Dis       Date:  1997-11       Impact factor: 4.982

4.  Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice.

Authors:  B Stauch Slusher; K C Rissolo; P F Jackson; L M Pullan
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 5.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 6.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 7.  Glutamate receptors and Parkinson's disease: opportunities for intervention.

Authors:  Michael J Marino; Ornella Valenti; P Jeffrey Conn
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Effect of L-arginine/nitric oxide pathway on MPP(+)-induced cell injury in the striatum of rats.

Authors:  M Santiago; A Machado; J Cano
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

Review 9.  The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention.

Authors:  Amanda L Sheldon; Michael B Robinson
Journal:  Neurochem Int       Date:  2007-04-19       Impact factor: 3.921

Review 10.  Towards an understanding of the role of glutamate in neurodegenerative disorders: energy metabolism and neuropathology.

Authors:  L Turski; W A Turski
Journal:  Experientia       Date:  1993-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.